Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Subscribe To Our Newsletter & Stay Updated
